Abstract
Inorganic polyphosphate (PolyP) plays an essential role in microbial stress adaptation, virulence and drug tolerance. The genome of Mycobacterium tuberculosis encodes for two polyphosphate kinases (PPK-1, Rv2984 and PPK-2, Rv3232c) and polyphosphatases (ppx-1, Rv0496 and ppx-2, Rv1026) for maintenance of intracellular PolyP levels. Microbial polyphosphate kinases constitute a molecular mechanism, whereby microorganisms utilize PolyP as phosphate donor for synthesis of ATP. In the present study we have constructed ppk-2 mutant strain of M. tuberculosis and demonstrate that PPK-2 enzyme contributes to its ability to cause disease in guinea pigs. We observed that ppk-2 mutant strain infected guinea pigs had significantly reduced bacterial loads and tissue pathology in comparison to wild type infected guinea pigs at later stages of infection. We also report that in comparison to the wild type strain, ppk-2 mutant strain was more tolerant to isoniazid and impaired for survival in THP-1 macrophages. In the present study we have standardized a luciferase based assay system to identify chemical scaffolds that are non-cytotoxic and inhibit M. tuberculosis PPK-2 enzyme. To the best of our knowledge this is the first study demonstrating feasibility of high throughput screening to obtain small molecule PPK-2 inhibitors.
Similar content being viewed by others
Introduction
Inorganic polyphosphate (PolyP) is a linear polymer of inorganic phosphate linked by phosphoanhydride bond1. PolyP is ubiquitously present in all domains of life (archaea, bacteria and eukarya) and plays an important role in various cellular physiological functions2,3,4. These functions include processes such as substitute for ATP in enzymatic reactions, chelator of divalent metal ions, phosphate reservoir and microbial adaptation to numerous stress conditions2,3,4,5,6. In bacterial pathogens, polyphosphate kinase -1 (PPK-1) catalyzes the reversible transfer of the terminal phosphate group of ATP to form long chain polyphosphates and the exopolyphosphatase (PPX) enzyme cleaves the phosphoanhydride bonds of PolyP to generate inorganic phosphate7,8,9. The intracellular PolyP levels in bacteria fluctuate upon its exposure to various stress conditions and decrease in PolyP levels is associated with impairment of several important structural and cellular functions such as motility, quorum sensing, biofilm formation and virulence4,10,11,12,13,14,15,16,17,18,19. In addition to its PolyP synthetic activity, PPK-1 also utilizes PolyP as phosphate donor for synthesis of nucleoside triphosphates from nucleoside diphosphates. In case of E. coli PPK-1, the order of substrate specificity for reverse reaction is ADP>GDP>CDP or UDP20.
In addition to PPK-1, another widely conserved enzyme in PolyP metabolism is polyphosphate kinase 2 (PPK-2) enzyme21. PPK-2 enzyme contains motif for phosphate binding (P-loop, GXXXXGK) and is broadly classified into three subfamilies, class I, II and III based on their substrate specificity22. Class I and II PPK-2 enzymes catalyze nucleoside diphosphate and nucleoside monophosphate phosphorylation whereas class III PPK-2 enzyme is able to synthesize nucleoside triphosphates directly from nucleoside monophosphates22,23,24,25. PPK-2 from Pseudomonas aeruginosa is upregulated by >100 fold during stationary phase and PPK-2 derived GTP is required for alginate production, the exopolysaccharide that envelopes the bacteria23,26. In addition, PPK-2 has also been demonstrated to mediate an important role in stress tolerance and pathogenesis of Campylobacter jejuni25.
M. tuberculosis genome harbors enzymes involved in both PolyP synthesis (PPK-1, Rv2984) and its utilization (PPK-2, Rv3232c and PPX, Rv0496 and Rv102627). In vitro quantification experiments revealed that mycobacteria accumulates PolyP at later stage of growth, upon exposure to stress conditions such as oxidative, nitrosative, nutritional, low oxygen and drugs such as rifampicin (Rif), levofloxacin (Levo), Isoniazid (Inh) and Gentamycin (Gm)28,29. Several studies demonstrate that any dysregulation in PolyP levels is associated with impaired survival of M. tuberculosis in macrophages and guinea pigs29,30. We have also previously shown that PolyP deficiency is associated with increased susceptibility of M. tuberculosis to front-line TB drugs29. PPK-2 enzyme from M. tuberculosis has been biochemically characterized, forms an octameric multimer, undergoes auto-phosphorylation and rates of PolyP dependent ATP synthesis are approximately 800 folds greater than the rates of PolyP synthesis31. In another study it has been shown that PPK-2 homolog regulates intracellular nucleoside triphosphate levels by interacting with Nucleoside diphosphate kinase A (NdkA) and contributes to M. smegmatis adaptation to conditions such as heat, acidic or hypoxia32.
In this study, we have cloned, expressed and purified M. tuberculosis PPK-2 enzyme for further biochemical characterization. We have constructed ppk-2 mutant strain of M. tuberculosis using temperature sensitive mycobacteriophages and compared the growth of various strains in vitro, in macrophages and guinea pigs. We demonstrate that PPK-2 enzyme is important for M. tuberculosis to establish disease in guinea pigs. Subsequently, we have screened a small molecule library and identified novel chemical scaffolds that are non-cytotoxic and inhibit PPK-2 enzyme in a dose dependent manner.
Results
Biochemical characterization of M. tuberculosis PPK-2
M. tuberculosis PPK-2 enzyme belongs to P-loop kinases superfamily and possesses both highly conserved Walker A and Walker B motif21,24 (Fig. S1). The Walker A motif (or P-loop, GXXXXGK) binds the β and γ phosphates of ATP whereas the conserved Asp residue in Walker B motif (DRS) coordinates with Mg2+ ion bound to β and γ phosphates residues of ATP. For biochemical characterization, the ppk-2 gene was PCR amplified, cloned into pMAL-c2x and purified as MBP-tagged protein using amylose resin as per manufacturer’s recommendations. The purified MBP-PPK-2 fractions were pooled, dialyzed, concentrated and assayed for PPK-2 activity. In our enzymatic assays we observed that MBP-PPK-2 possesses Ndk-like activity utilizing PolyP as the phosphate donor for ATP synthesis. We show that ATP synthetic activity of PPK-2 increased in the presence of both ADP and enzyme in a dose dependent manner (Fig. 1a,b). As shown in Fig. 1c, majority of ATP synthesis by PPK-2 was attained in initial 5 minutes of the enzymatic reaction. In contrast to purified PPK-1 enzyme, MBP-PPK-2 could also utilize short chain polyphosphates, PolyP3 as the phosphate donor, however, its activity increased in the presence of long chain polyphosphates PolyP17 or PolyP4529 (Fig. 1d). It has been demonstrated that PPK-2 enzyme undergoes autophosphorylation and these residues (His115, His247) are essential for activity32. For mutational analysis in this study Gly73 and Lys75 located in the P-loop motif were selected. Besides these, the highly conserved Phe125 and Trp129 residues surrounding the Walker B motif were also shortlisted for mutational studies. We next compared the activity of wild type and mutant PPK-2 enzymes in our enzymatic assays (Fig. 1e). We observed that purified MBP-K75APPK-2, MBP-F125APPK-2 and MBP-W129APPK-2 proteins had significantly reduced activity as compared to wild type protein (Fig. 1e). However the activity of MBP-G72APPK-2 and wild type proteins were similar in our enzymatic assays (Fig. 1e).
Expression of PPK-2 during different in vitro conditions
Identifying the conditions under which PPK-2 is upregulated is essential to understand its role in M. tuberculosis physiology. In the present study we have performed quantitative real time PCR (qRT-PCR) to measure ppk-2 transcript levels under various growth conditions and upon exposure to multiple stress conditions in vitro (Fig. 1f). We observed that ppk-2 transcripts were upregulated by 2.0–2.5 fold during mid-log, late-log and stationary phase stages of M. tuberculosis growth in liquid cultures (Fig. 1f). However, a marginal decrease in ppk-2 transcript level was observed upon exposure of M. tuberculosis to nutritional stress. We also report that exposure to either oxidative or nitrosative stress conditions had no effects on ppk-2 transcript levels (Fig. 1f). We next investigated the effects of drug exposure on ppk-2 transcription and observed exposure of M. tuberculosis to both 10x and 1x MIC99 concentration of isoniazid, gentamycin and ethambutol had minimal effects on ppk-2 transcript levels (Fig. 1f).
Construction and characterization of ppk-2 mutant strain
To investigate the role of PPK-2 enzyme in M. tuberculosis stress adaptation and virulence, we constructed ppk-2 mutant strain using temperature sensitive mycobacteriophages33 (Fig. 2a). The replacement of open reading frame of PPK-2 enzyme with hygromycin resistance gene in the genome of ppk-2 mutant strain was confirmed by Southern blot and qRT-PCR studies (Fig. 2b,d). In a recent study by Chuang et al, it has been shown that ppk-2 is co-transcribed along with its upstream genes, Rv3233c and Rv3234c and genes downstream to ppk-2 (Rv3231c and Rv3230c) are co-transcribed independently in a single transcript34. To design our strategy for construction of complemented strain, qRT-PCR was performed to determine whether replacement of ppk-2 with hygromycin resistance gene had any polar effect on transcription of its neighboring genes (Fig. 2c). In concordance with previous reports, Rv3231c, Rv3233c and Rv3234c transcript levels were comparable in both wild type and ppk-2 mutant strain, thereby suggesting lack of polar effect in the mutant strain34. The ppk-2 complemented strain was constructed by re-introducing a copy of ppk-2 in trans using an integrative expression vector pJEB402 to yield ppk-2 complemented strain. The restoration of ppk-2 transcript levels in ppk-2 complemented strain was verified by qRT-PCR (data not shown). We also compared the transcript levels of ppk-1 (Rv2984) and ppx (Rv0496 and Rv1026) enzymes in both wild type and ppk-2 mutant strain at different stages of growth (Fig. 2d). Similar to previous studies we observed that transcript levels of ppk-1 and ppx were reduced in ppk-2 mutant strain relative to wild type strain at late-log and stationary phase growth conditions (Fig. 2d). However, the transcript levels for these PolyP metabolic enzymes remained unaltered in both wild type and ppk-2 mutant strain during mid-log stage of growth34 (Fig. 2d).
Numerous studies have shown that bacterial strains harboring mutations in PolyP metabolic enzymes display altered growth defect in liquid medium, colony morphology and biofilm formation. As shown in Fig. 2e, the ppk-2 mutant strain had a slight growth defect (~2.0 fold) in liquid medium and we were able to restore this defect in the ppk-2 complemented strain. In this study we observed that wild type, ppk-2 mutant strain and ppk-2 complemented strains displayed similar colony morphology in solid medium and biofilm formation in detergent free Sauton’s medium (Fig. S2a,b). In a study by Chuang et al, TEM analysis revealed that M. tuberculosis strains accumulating PolyP are shorter in length as compared to wild type bacilli28. However, in our study, we observed that the cell wall architecture and bacterial length of wild type and ppk-2 mutant strain were similar to each other (Fig. 2f).
PPK-2 is associated with reduced INH susceptibility and required for intracellular survival in macrophages
In Campylobacter jejuni, deletion of ppk-2 impairs its ability to survive upon exposure to nutritional and osmotic stress25. M. tuberculosis is a extremely successful intracellular pathogen by virtue of its ability to sense and adapt to diverse range of stress conditions such as low oxygen, acidic pH and nutrient deprivation. Therefore, we next compared the survival rates of wild type, ppk-2 mutant and ppk-2 complemented strain upon exposure to various stress conditions such as oxidative, nitrosative, nutritional, low oxygen and in THP-1 macrophages (Fig. 3). We observed that ppk-2 mutant strain was comparable to wild type strain in its ability to survive upon exposure to either oxidative, nitrosative or nutritional stress (Fig. 3a–c).
Consistent with previously published reports, we observed that intracellular PolyP levels are elevated in ppk-2 mutant strain in comparison to wild type and ppk-2 complemented strains34 (data not shown). We had earlier reported that PolyP deficiency is associated with enhanced susceptibility of M. tuberculosis to front-line TB drugs29. Therefore, we next investigated whether PolyP accumulation in ppk-2 mutant strain is associated with enhanced tolerance against front-line TB drugs. We observed that as compared to the wild type strain, ppk-2 mutant strain was approximately 3.0–4.0 fold more tolerant upon exposure to cell wall inhibitor, INH (Fig. 3d, p < 0.05). However, the percentage persisters were similar for both wild type and ppk-2 mutant strain upon exposure to other known TB drugs such as Rif, Levo or Gm (Fig. 3d). These results suggest that various metabolic pathways contribute to the phenomenon of persistence in a drug-specific manner. As shown in Table S1, minimum inhibitory concentration (MIC99) values for various drugs tested in the study were comparable for both wild type and ppk-2 mutant strain. In order to understand the role of PPK-2 enzyme in M. tuberculosis adaptation to low oxygen conditions, we next compared the growth of wild type, ppk-2 mutant and ppk-2 complemented strains in hypoxia. We observed that the bacterial numbers were 3.0–4.0 fold more in the case of ppk-2 mutant strain in comparison to wild type strain at day-56 and day-65 in Wayne hypoxia model (Fig. 3e). The bacterial numbers were restored in the ppk-2 complemented strain upon reintroduction of PPK-2 expression in the mutant strain (Fig. 3e). To investigate the role of PPK-2 in intracellular survival of M. tuberculosis, THP-1 macrophages were infected with either wild type or ppk-2 mutant or ppk-2 complemented strain at an MOI of 1:1. As shown in Fig. 3f, we observed that wild type, ppk-2 mutant and ppk-2 complemented strain displayed similar growth kinetics within macrophages upto 4 days post-infection. However, ppk-2 mutant strain displayed a growth defect of 2.0-fold in comparison to the wild type strain and ppk-2 complemented strain at day 6 post-infection (Fig. 3f, p < 0.05).
The ppk-2 mutant strain of M. tuberculosis is attenuated for growth in vivo
Next, we determined the role of PPK-2 in M. tuberculosis ability to grow and persist in vivo by infecting guinea pigs with various strains. For these experiments, guinea pigs were infected via aerosol route with log10 1.93 ± 0.06, log10 2.13 ± 0.1, log10 2.06 ± 0.1 (these values are log10 number of CFU/lung) delivered in the case of wild type, ppk-2 mutant and ppk-2 complemented strains, respectively. Gross pathology analysis revealed that lung tissues from wild type and ppk-2 complemented strains infected groups showed discrete multiple large tubercles, whereas their numbers and size were fewer in ppk-2 mutant infected guinea pigs (Fig. 4a). However, the total lung weight from wild type, ppk-2 mutant and ppk-2 complemented strains infected guinea pigs were almost identical (data not shown). As expected M. tuberculosis growth was observed in all three groups, while lungs infected with wild type bacteria had 12.0 fold higher bacterial numbers in comparison to lungs infected with ppk-2 mutant strain at 4 weeks post-infection (Fig. 4b, p < 0.01). Similarly, the splenic bacterial counts in ppk-2 mutant infected guinea pigs (log10 3.6 ± 0.88) were significantly lower by 7.5 fold as compared to wild type infected guinea pigs (log10 4.5 ± 0.084, p < 0.01). The ppk-2 mutant strain exhibited a more dramatic growth defect of 18.5 folds and 42.0 folds in lungs and spleens, respectively at day-56 post-infection (Fig. 4c, p < 0.01). As shown in Fig. 4b,c, we observed that bacterial loads in tissues from ppk-2 complemented strains were increased to those observed in ppk-2 mutant infected guinea pigs at both 4 weeks and 8 weeks post-infection.
In agreement with these growth patterns we observed similar extent of tissue damage with large granulomas in the lung parenchyma from all three groups at 4 weeks post-infection (Fig. 5). Majority of these lung granulomas were composed primarily of epitheloid cells with peripheral lymphocytic rich zones while few granulomas showed necrotic centers with acute inflammatory cellular infiltration in and around the necrotic areas (Fig. 5a). A more detailed quantitative analysis revealed that the total granuloma scores in lung sections from guinea pigs infected with the wild type and ppk-2 mutant were 14.0 and 19.0 respectively at 4 weeks post-infection (Fig. 6a). As expected, at 8 weeks post-infection significantly reduced tissue damage was observed in lung tissue sections from ppk-2 mutant infected guinea pigs as compared to wild type and ppk-2 complemented infected guinea pigs (Fig. 5b). As shown in Fig. 6a, total granuloma scores in lung sections of wild type infected guinea pigs were significantly higher by ~7.0 fold in comparison to those obtained in sections from ppk-2 mutant infected guinea pigs at 8 weeks post-infection (p < 0.05). The section from wild type infected guinea pigs displayed large granulomas with central necrosis whereas ppk-2 mutant infected sections showed granulomas lacking necrotic centers and comprised mainly of epitheloid cells and lymphocytes. We observed that both number and diameter of granulomas (primary and secondary) were higher in lung sections from wild type infected guinea pigs in comparison to sections from guinea pigs infected with ppk-2 mutant strain (Fig. 6b, p < 0.01 and 6c, p < 0.001). The percentage of surface area involved by inflammation in lung sections from wild type infected guinea pigs (15.80 ± 6.2) was significantly higher in comparison to lung sections from ppk-2 infected guinea pigs (0.833 ± 0.54) at 8 weeks post-infection (p < 0.01). We also observed that genetic complementation of ppk-2 mutant strain with wild type copy under the control of hsp60 promoter increased lung involvement, thereby, indicating attenuation observed in vivo was due to disruption of ppk-2 in M. tuberculosis.
Identification of PPK-2 inhibitors using high throughput approach
In order to identify PPK-2 inhibitors, an endpoint assay system was developed that is amenable to 96-well format for high throughput screening. For initial standardizations, various parameters such as buffer pH, ion concentration and reaction time were investigated and optimum PPK-2 activity was observed in assay conditions; 50 mM Tris-Cl pH-7.4, 10 mM (NH4)2SO4 and 10 mM MgCl2 after 20 minutes of incubation at 37 °C (data not shown). NCI-DTP library comprising of 2300 compounds belonging to either diversity set, mechanistic set or natural product set was screened to identify novel inhibitors for PPK-2 enzyme. Preliminary screening at 100 μM concentration yielded 12 compounds with a hit rate of 0.5% that inhibited PPK-2 activity by >50%. As shown in Fig. 7a,b seven compounds inhibited PPK-2 activity by >50% and five compounds displayed 50–75% inhibition of PPK-2 activity. However, in our repeat inhibition experiments only 10 scaffolds inhibited PPK-2 dependent ATP synthesis by >50%. Cross-reactivity of these inhibitors with luciferase enzyme would be a major concern in further validation of these primary hits as PPK-2 inhibitors. Therefore, we compared the ability of these identified hits to inhibit luciferase and PPK-2 enzyme in vitro at 100 μM concentration. We observed that six out of these 10 compounds inhibited both luciferase and PPK-2 enzyme to similar extent (data not shown). As shown in Fig. 7c remaining 4 compounds NSC-35676, NSC-30205, NSC-345647 and NSC-9037 specifically inhibited PPK-2 enzyme by >80% at 100 μM concentration. As expected, these scaffolds inhibited PPK-2 enzyme in our in vitro assays in a dose dependent manner (Figs 7d and 8).
In our WST-1 based cell viability assays, NSC9037 and NSC 35676 were non-cytotoxic to THP-1 cells even at 50 μM concentration (highest concentration tested in the study). Remaining two scaffolds NSC-35647 and NSC-30205 were cytotoxic against THP-1 macrophages with TC50 values of 5 and 10 μM, respectively. The results presented in this study demonstrate that PPK-2 is an in vivo drug-target and contributes to M. tuberculosis ability to cause disease in guinea pigs. The 96-well standardized luciferase based assay system could be explored further to identify more potent PPK-2 specific non-cytotoxic inhibitors.
Discussion
M. tuberculosis is a extremely successful intracellular pathogen and possesses various virulence determinants such as extra-cytoplasmic sigma factors and two component systems that enable it to evade host immune response and adapt to various stress conditions encountered in the host35,36. PolyP, a linear polymer of inorganic phosphate accumulates in M. tuberculosis upon stress and drug-exposure in vitro28,29. The genome of M. tuberculosis harbors enzymes involved in both PolyP synthesis and utilization. PPK-1, PPK-2 and PPX have been biochemically characterized and in comparison to the parental strain, ppk-1 and ppx mutant M. tuberculosis strains are attenuated for growth in guinea pigs28,29. In the present study we have performed experiments to i) understand the role of PPK-2 enzyme in M. tuberculosis physiology and virulence and ii) to identify small molecule inhibitors for PPK-2 enzyme. In this study, we report that M. tuberculosis PPK-2 belongs to class-I subfamily and is able to utilize PolyP of different chain lengths as phosphate donor for synthesis of ATP. In addition to previously identified essential amino acids His-115, His-245 and Gly-74, we report that mutation of Lys-75, Phe-125 and Trp-129 significantly reduced the activity of PPK-2 enzyme in vitro32.
Previous studies have demonstrated that PPK-2 enzyme interacts with NdkA enzyme to maintain intracellular GTP levels in M. smegmatis. The ppk-2 mutant of M. smegmatis displayed increased ATP/GTP ratios and was compromised in its ability to survive under conditions such as heat or acidic or hypoxia32. Concordantly, the ATP/GTP ratios were also marginally increased in ppk-2::tn of M. tuberculosis in comparison to the wild type strain34. In this study we have performed experiments to understand the significance of PPK-2 in stress adaptation and virulence using guinea pigs. The ppk-2 mutant strain was constructed using temperature sensitive mycobacteriophages and it displayed a slight growth defect in stationary phase as compared to the wild type strain. We observed that increase in ATP/GTP and PolyP levels is associated with enhanced tolerance of M. tuberculosis towards INH. This tolerance phenomenon was INH specific as both wild type and ppk-2 mutant strains were equally susceptible to other drugs evaluated in the study. The observed reduced susceptibility towards INH was due to presence of INH-tolerant persisters and not due to emergence of INH-resistant mutant strains. This INH tolerant phenotype is consistent with enhanced and reduced INH susceptibility phenotype observed for PolyP deficient (ppk-1) and PolyP accumulating (ppx) mutant strains of M. tuberculosis, respectively29,30. We also observed that both wild type and ppk-2 mutant strain of M. tuberculosis were susceptible to similar levels upon exposure to other stress conditions in vitro.
The low-dose aerosol guinea pig model was used to determine the effect of ppk-2 deletion on M. tuberculosis growth in vivo. Although, the ppk-2 mutant was implanted at a higher dose, the number of bacteria were 12.0 and 7.5 folds lower in lungs and spleens, respectively, in comparison to wild type infected guinea pigs at 4 weeks post-infection. This survival defect increased to approximately 18.5 fold and 42.0 fold in lungs and spleens, respectively at day 56 post-infection. We observed incomplete restoration of wild type phenotype following complementation of ppk-2 mutant strain with wild type copy of ppk-2. Histological analysis were in concordance with bacterial burdens as fewer granulomas were observed in ppk-2 mutant infected guinea pigs as compared to wild type and ppk-2 complemented guinea pigs at 8 weeks post-infection. The growth defect associated with the in vivo survival of ppk-2 mutant strain was more apparent in guinea pigs in comparison to mouse infection studies34. A possible explanation for these contradicting findings could be use of different animal models for respective virulence studies. The guinea pigs following M. tuberculosis infection form classically appearing caseous granulomas whereas granulomas observed in mouse are diffuse37. In addition, similar to human tuberculosis lesions, the oxygen levels are profoundly reduced in guinea pig granulomas in comparison to mouse granulomas. Another variation in these studies was the nature of mutant strains used for animal experiments. Chaung et al, utilized ppk-2:Tn mutant for their mice infection studies, whereas in our guinea pig experiments we have employed a strain in which PPK-2 open reading frame has been replaced by hygromycin resistance gene34. However, a limitation of our study is the lack of cytokine data that would enable us to understand the contribution of host immune response to control infection caused by ppk-2 mutant strain of M. tuberculosis. Our findings are similar to other studies where survival phenotypes associated with mutant strains are more apparent in guinea pigs as compared to mice38,39. The observed survival defect of ppk-2 mutant strain is similar to the phenotype observed for another PolyP accumulating strain deficient in exopolyphosphatase, Rv049630. These observations suggest that PPK-2 contributes to M. tuberculosis adaptation to conditions implicated by the host immune response specifically in guinea pigs. Similar to our observations, ppk-2 deletion is also associated with survival defect of Campylobacter jejuni within human intestinal epithelial cells25.
Despite identification and validation of various novel drug targets and scaffolds, a major challenge in the field of chemotherapy is emergence of various drug-resistant TB strains40. Therefore, validation of newer in vivo drug targets and identification of scaffolds with novel mechanism of action is urgently required. These identified newer scaffolds should i) target heterogeneous bacterial population ii) target MDR and XDR M. tuberculosis strains iii) be compatible with the current TB regimen and iv) shorten the duration of lengthy TB chemotherapy41. Recently, FDA has approved bedaquiline, a drug that target M. tuberculosis ATP synthase for treatment of MDR-TB patients42,43. We hypothesize that under conditions where ATP levels are lowered due to reduction in ATP synthase activity, M. tuberculosis can utilize accumulated PolyP as phosphate donor for synthesis of ATP. This PolyP dependent ATP synthesis might be important for reactivation of M. tuberculosis from dormancy. The results presented in this and other studies demonstrate that PolyP metabolic enzymes are essential for M. tuberculosis growth in guinea pigs and are promising in vivo drug targets for identification of novel scaffolds28,29,34. Although numerous studies have validated these enzymes as drug-targets, to the best of our knowledge this is the first study where high throughput screening has been performed to identify novel PPK-2 inhibitors. Using 96-well luciferase based assay system we have identified two scaffolds NSC- 9037 and NSC-35676 as primary lead compounds that are non-cytotoxic and specific in their ability to inhibit PPK-2 enzyme in vitro in a dose dependent manner. These scaffolds might be also useful to combat infections caused by other bacterial pathogens such as V. cholerae and P. aeruginosa that encodes for PPK-2 protein with considerable homology to M. tuberculosis protein.
In summary, we report that PPK-2 is required for M. tuberculosis growth during acute and chronic stage of infection. The identified PPK-2 specific scaffolds can be explored further to design structural analogs that are non-cytotoxic and are more potent against M. tuberculosis PPK-2 enzyme in vitro. These results demonstrate the feasibility of 96-well luciferase based assay system to screen more libraries for identification of bacterial polyphosphate kinases inhibitors.
Methods
Bacterial strains and growth conditions
Bacterial strains and plasmids used in this study are listed in Table 1. E. coli strains were cultured in Luria-Bertani (LB) Miller medium. The mycobacterial strains were cultured in Middlebrook 7H9 broth (Difco, Becton, NJ, USA) supplemented with 10% albumin dextrose saline, 0.2% glycerol and 0.05% Tween-80 or in Middlebrook 7H11 agar plates at 37 °C as previously described29. The in vitro growth characteristics of various mycobacterial strains in the study was determined by measuring either absorbance at 600 nm or by plating 10-fold serial dilutions on MB 7H11 plates. The antibiotics were used at the following concentrations; ampicillin, 100 μg/ml; kanamycin (50 μg/ml for E. coli and 25 μg/ml for mycobacteria) and hygromycin B (150 μg/ml for E. coli and 50 μg/ml for mycobacteria). Standard protocols were followed for routine molecular biology experiments.
Multiple sequence alignment studies
PPK-2 protein sequences from various microorganisms were retrieved from the National Centre of Biotechnology Institute (NCBI) protein database. Multiple sequence alignment was performed using Clustal omega software (version 1.2.0, http://www.ebi.ac.uk/Tools/msa/clustalo/) and edited using Genedoc software version 2.7.00044.
Biochemical characterization of M. tuberculosis PPK-2 enzyme
For biochemical characterization, 888 bp region encoding for PPK-2 was PCR amplified using gene specific primers and cloned into a prokaryotic expression vector, pMAL-c2x (New England Biolabs, Ipswich, MA, USA). The primers used in this study are listed in Table S2. The recombinant plasmid pMAL-ppk-2 was transformed into E. coli TB-1 cells and recombinant protein was induced by 1 mM IPTG addition and purified using amylose resin as per manufacturer’s recommendations. The purified protein fractions were pooled, concentrated and stored in storage buffer (20 mM Tris-Cl, pH-7.4, 200 mM NaCl, 1 mM EDTA and 10% glycerol) till further use. For biochemical characterization, glycine 72, lysine 75, phenylalanine 125 and tryptophan 129 amino acid residues were mutated to alanine residue by overlap extension PCR as per standard protocols and mutant genes were cloned into pMAL-c2x. PPK-2 activity assays were performed in buffer containing 50 mM Tris-Cl, pH-7.4, 10 mM (NH4)2SO4, 10 mM MgCl2 and 1 μM purified PPK-2 proteins. The amount of ATP generated in the enzyme reaction was quantified using Bactitre glo reagent as per manufacturer’s recommendations (Promega, Madison, WI, USA).
Real time PCR studies
For qRT-PCR studies, M. tuberculosis H37Rv strains were cultured till early-log phase and subsequently exposed to various stress conditions and drugs as described previously29. mRNA was isolated by bead beating, purified using RNAeasy column and DNase I treated using Ambion DNA-free kit (Invitrogen Corporation, Carlsbad, CA, USA). 1 μg of Dnase I treated mRNA was used for cDNA synthesis using Superscript III reverse transcriptase. In vitro synthesized cDNA was used as template for quantitative PCR using gene specific primers. The primer sequences used for qRT-PCR studies have been listed in Table S2. The cycle threshold (CT) obtained for each gene of interest was normalized with that of sigA, housekeeping gene in order to obtain a normalized CT value. The transcript levels of ppk-2 neighboring genes (Rv3231c, Rv3233c and Rv3234c) and enzymes involved in PolyP metabolism (ppk-1, ppk-2, ppx-1 and ppx-2) were measured and compared in both wild type and ppk-2 mutant strain at mid-log, late-log and stationary phase growth conditions.
Construction of ppk-2 mutant and complemented strains
Primer pairs ppk-2 UpF/UpR and ppk-2 DnF/DnR were designed to generate 800 bp upstream and downstream amplicons, respectively. These amplicons were gel eluted and cloned into cosmid vector pYUB854 flanking hygromycin resistance gene33. The recombinant cosmid pYUB854-Δppk2 was packaged into phagemid phAE-159 using Gigapack III packaging extract (Agilent Technologies, Santa Clara, CA, USA). The ppk-2 mutant strain of M. tuberculosis was constructed by homologous recombination using these temperature sensitive mycobacteriophages as per standard protocols33. The replacement of open reading frame for PPK-2 with hygromycin resistance gene in ppk-2 mutant strain was confirmed by Southern blot and qRT-PCR analysis. For construction of ppk-2 complemented strain, ppk-2 DNA fragment was PCR amplified and cloned in mycobacterial shuttle integrative vector pJEB40245. The recombinant plasmid, pJEB-ppk-2 was electroporated into ppk-2 mutant strain and restoration of ppk-2 expression in the mutant strain was confirmed by qRT-PCR. The primer sequences for ppk-2 mutant and ppk-2 complemented strain construction are listed in Table S2.
Growth kinetics and in vitro stress experiments
M. tuberculosis wild type, ppk-2 mutant and ppk-2 complemented strains were cultured in MB 7H9 medium and their growth characteristics were monitored by measuring CFU/ml. For in-vitro stress experiments various strains were cultured, harvested at OD600nm 0.3–0.4, washed with MB7H9 medium and exposed to either oxidative stress (5 mM H2O2) for 24 hours or nitrosative stress (5 mM NaNO2) for 72 hours or nutritional stress (1x tris buffered saline-tween-80) for 7 days as per standard protocols29. For in vitro drug tolerance, various strains were grown till mid-log stage (OD600nm 1.5–2.0) and subsequently exposed to drugs with different mechanism of action such as Rif (transcriptional inhibitor), Levo (replication inhibitor), Inh (cell wall inhibitor) and Gm (translational inhibitor). After 14 days of drug-exposure, bacilli were harvested, washed twice with antibiotic free medium and resuspended in 1 ml of MB7H9 medium. The enumeration of viable bacteria was performed by plating 100 μl of 10-fold serial dilutions on MB7H11 plates in duplicates. For electron microscopy analysis, various strains were grown till late-log phase, fixed and stained with alcoholic uranyl acetate and alkaline lead citrate as per standard protocols29. The electron microscopy images were captured using Morgagni 268D transmission electron microscope (Fei company, Hillsbro, OR, USA). For MIC99 determination, various drugs were tested against wild type and ppk-2 mutant strain from 50 μM to 0.04875 μM concentration in 96-well plates as per standard protocols. The growth inhibition in the presence of drugs was measured macroscopically using an inverted plate reader method at least two independent times.
Infection of THP-1 macrophages with M. tuberculosis
THP-1 cells were maintained at 37 °C, 5% CO2 in RPMI medium supplemented with 10% fetal bovine serum (FBS, Invitrogen Corporation, Carlsbad, CA, USA). THP-1 monocytes were differentiated into macrophages by overnight addition of 15 nM phorbol-12-myristate-13-acetate (PMA). Macrophages were seeded at a cell density of 2 × 105 in a 12 well plate and infected with various M. tuberculosis strains at an MOI of 1:1. After 4 hours post-infection, macrophages were washed and extracellular bacteria were removed by overlaying macrophages with RPMI medium containing 200 μg/ml amikacin for 2 hours. Subsequently, macrophages were washed twice with antibiotic free medium and overlayed with RPMI medium supplemented with 10% FBS. At days 0, 2, 4 and 6 post-infection, macrophages were lysed in 1× PBS containing 0.1% Triton X-100 and bacterial enumeration was done as described above.
In vivo guinea pig experiments
Protocols for the animal experiments were reviewed and approved by the Institutional Animal Ethics Committee of International Centre for Genetic Engineering and Biotechnology (ICGEB/AH/2012/TACF/THSTI-2). Pathogen free out-bred female guinea pigs (Duncan Hartley strain, weight 300–350 g) were purchased from Lala Lajpat Rai University of Veterinary and Animal Sciences, Hisar, India. Guinea pigs were housed at Tuberculosis Aerosol challenge facility according to the procedures of the ICGEB animal care committee. For animal experiments, guinea pigs were infected via aerosol route using a Madison aerosol chamber with approximately 100 CFU of either M. tuberculosis H37Rv or ppk-2 mutant or ppk-2 complemented strain. Guinea pigs (n = 6/7) were sacrificed at 28 days and 56 days post-infection for determination of lung and splenic bacillary loads as described previously29. For histological studies, portion of lungs were fixed in 10% formalin, embedded in paraffin wax and stained with hematoxylin and eosin. The embedded tissues were coded, the extent of tissue damage and cellular infiltration was analysed by a pathologist as described previously29. The tissue samples were coded and evaluation of lung sections for granulomatous organization was performed by a pathologist having no prior knowledge of the experimental groups. The whole section of lung was examined and the number of granulomas were counted. Each granuloma was graded by the criteria as described previously29,46. Briefly, granulomas with necrosis were given a score of 5, granulomas with centrally placed epitheloid cells but no necrosis were given a score of 2.5 and granulomas with fibrous connective tissue surrounding lymphocytes and epitheloid cells were given a score of 1. Total granuloma score was obtained by multiplying number of granulomas of each type by the score and then adding them up to obtain a total granuloma score for each sample.
High throughput screening to identify PPK-2 inhibitors
The luciferase based assay system was adapted to a 96-well format to identify novel PPK-2 small molecule inhibitors. For inhibition studies, an endpoint enzyme reaction was performed in assay conditions as described earlier in the absence and presence of inhibitor. The compounds screened belonged to small molecule library procured from National Cancer Institute–Developmental Therapeutic Program (NCI-DTP; http://dtp.nci.nih.gov/repositories.html). NCI-DTP library consists of 2300 compounds belonging to diversity set, mechanistic set or natural product set. Preliminary screening was performed at 100 μM concentration and all reaction plates included controls such as no buffer, no substrate, no enzyme and complete reaction control. For inhibition studies, PPK-2 enzyme was pre-incubated with small molecules for 10 minutes at 37 °C and the enzyme reaction was initiated by addition of 10 μM of PolyP17. The amount of ATP generated in enzymatic reactions was measured and percentage inhibition for each compound was calculated and plotted. Half-maximal inhibitory (IC50) concentration for identified primary hits (hits inhibiting PPK-2 activity by >50%) was determined by performing activity assays in the presence of increasing concentration of compounds in triplicates. The cellular cytotoxicity (TC50) for these primary hits against THP-1 macrophages was determined as described previously using Cell Proliferation WST-1 kit as per manufacturer’s recommendations47 (Sigma Aldrich, St. Louis, MI, USA).
Statistical analysis
Graph Pad Prism 5 software (version 5.01, GraphPad Software Inc., CA) was used for the generation of graphs. Differences were considered statistically significant with P < 0.05.
Ethics statement
This study was carried out in accordance with the guidelines provided by committee for the purpose of control and supervision on experiments on animals (CPCSEA, Govt. of India). The animal experiments were approved by the Animal ethics committee of the International Centre for genetic engineering and biotechnology, New Delhi, India (Approval No:- ICGEB/AH/2012/1/TACF-THSTI-2).
Additional Information
How to cite this article: Singh, M. et al Establishing Virulence Associated Polyphosphate Kinase 2 as a drug target for Mycobacterium tuberculosis. Sci. Rep. 6, 26900; doi: 10.1038/srep26900 (2016).
Change history
21 September 2020
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
02 November 2021
A Correction to this paper has been published: https://doi.org/10.1038/s41598-021-00316-4
References
Kulaev, I. S. Biochemistry of inorganic polyphosphates. Rev Physiol Biochem Pharmacol 73, 131–58 (1975).
Castuma, C. E., Huang, R., Kornberg, A. & Reusch, R. N. Inorganic polyphosphates in the acquisition of competence in Escherichia coli. J Biol Chem 270, 12980–3 (1995).
Kornberg, A. Inorganic polyphosphate: toward making a forgotten polymer unforgettable. J Bacteriol 177, 491–6 (1995).
Rao, N. N. & Kornberg, A. Inorganic polyphosphate supports resistance and survival of stationary-phase Escherichia coli. J Bacteriol 178, 1394–400 (1996).
Kornberg, A., Rao, N. N. & Ault-Riche, D. Inorganic polyphosphate: a molecule of many functions. Annu Rev Biochem 68, 89–125 (1999).
Brown, M. R. & Kornberg, A. The long and short of it-polyphosphate, PPK and bacterial survival. Trends Biochem Sci 33, 284–90 (2008).
Ahn, K. & Kornberg, A. Polyphosphate kinase from Escherichia coli. Purification and demonstration of a phosphoenzyme intermediate. J Biol Chem 265, 11734–9 (1990).
Akiyama, M., Crooke, E. & Kornberg, A. An exopolyphosphatase of Escherichia coli. The enzyme and its ppx gene in a polyphosphate operon. J Biol Chem 268, 633–9 (1993).
Wurst, H., Shiba, T. & Kornberg, A. The gene for a major exopolyphosphatase of Saccharomyces cerevisiae. J Bacteriol 177, 898–906 (1995).
Kuroda, A. et al. Role of inorganic polyphosphate in promoting ribosomal protein degradation by the Lon protease in E. coli. Science 293, 705–8 (2001).
Kuroda, A. et al. Inorganic polyphosphate kinase is required to stimulate protein degradation and for adaptation to amino acid starvation in Escherichia coli. Proc Natl Acad Sci USA 96, 14264–9 (1999).
Rao, N. N. & Kornberg, A. Inorganic polyphosphate regulates responses of Escherichia coli to nutritional stringencies, environmental stresses and survival in the stationary phase. Prog Mol Subcell Biol 23, 183–95 (1999).
Rao, N. N., Liu, S. & Kornberg, A. Inorganic polyphosphate in Escherichia coli: the phosphate regulon and the stringent response. J Bacteriol 180, 2186–93 (1998).
Rashid, M. H. & Kornberg, A. Inorganic polyphosphate is needed for swimming, swarming and twitching motilities of Pseudomonas aeruginosa. Proc Natl Acad Sci USA 97, 4885–90 (2000).
Rashid, M. H., Rao, N. N. & Kornberg, A. Inorganic polyphosphate is required for motility of bacterial pathogens. J Bacteriol 182, 225–7 (2000).
Rashid, M. H. et al. Polyphosphate kinase is essential for biofilm development, quorum sensing and virulence of Pseudomonas aeruginosa. Proc Natl Acad Sci USA 97, 9636–41 (2000).
Reusch, R. N. Transmembrane ion transport by polyphosphate/poly-(R)-3-hydroxybutyrate complexes. Biochemistry (Mosc) 65, 280–95 (2000).
Kim, K. S., Rao, N. N., Fraley, C. D. & Kornberg, A. Inorganic polyphosphate is essential for long-term survival and virulence factors in Shigella and Salmonella spp. Proc Natl Acad Sci USA 99, 7675–80 (2002).
Crooke, E., Akiyama, M., Rao, N. N. & Kornberg, A. Genetically altered levels of inorganic polyphosphate in Escherichia coli. J Biol Chem 269, 6290–5 (1994).
Kuroda, A. & Kornberg, A. Polyphosphate kinase as a nucleoside diphosphate kinase in Escherichia coli and Pseudomonas aeruginosa. Proc Natl Acad Sci USA 94, 439–42 (1997).
Zhang, H., Ishige, K. & Kornberg, A. A polyphosphate kinase (PPK2) widely conserved in bacteria. Proc Natl Acad Sci USA 99, 16678–83 (2002).
Motomura, K. et al. A new subfamily of polyphosphate kinase 2 (class III PPK2) catalyzes both nucleoside monophosphate phosphorylation and nucleoside diphosphate phosphorylation. Appl Environ Microbiol 80, 2602–8 (2014).
Ishige, K., Zhang, H. & Kornberg, A. Polyphosphate kinase (PPK2), a potent, polyphosphate-driven generator of GTP. Proc Natl Acad Sci USA 99, 16684–8 (2002).
Nocek, B. et al. Polyphosphate-dependent synthesis of ATP and ADP by the family-2 polyphosphate kinases in bacteria. Proc Natl Acad Sci USA 105, 17730–5 (2008).
Gangaiah, D. et al. Polyphosphate kinase 2: a novel determinant of stress responses and pathogenesis in Campylobacter jejuni. PLoS One 5, e12142 (2010).
Sundin, G. W. et al. Nucleoside diphosphate kinase from Pseudomonas aeruginosa: characterization of the gene and its role in cellular growth and exopolysaccharide alginate synthesis. Mol Microbiol 20, 965–79 (1996).
Cole, S. T. et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537–44 (1998).
Chuang, Y. M. et al. Deficiency of the novel exopolyphosphatase Rv1026/PPX2 leads to metabolic downshift and altered cell wall permeability in Mycobacterium tuberculosis. MBio 6, e02428 (2015).
Singh, R. et al. Polyphosphate deficiency in Mycobacterium tuberculosis is associated with enhanced drug susceptibility and impaired growth in guinea pigs. J Bacteriol 195, 2839–51 (2013).
Thayil, S. M., Morrison, N., Schechter, N., Rubin, H. & Karakousis, P. C. The role of the novel exopolyphosphatase MT0516 in Mycobacterium tuberculosis drug tolerance and persistence. PLoS One 6, e28076 (2011).
Shum, K. T. et al. Aptamer-mediated inhibition of Mycobacterium tuberculosis polyphosphate kinase 2. Biochemistry 50, 3261–71 (2011).
Sureka, K., Sanyal, S., Basu, J. & Kundu, M. Polyphosphate kinase 2: a modulator of nucleoside diphosphate kinase activity in mycobacteria. Mol Microbiol 74, 1187–97 (2009).
Bardarov, S. et al. Specialized transduction: an efficient method for generating marked and unmarked targeted gene disruptions in Mycobacterium tuberculosis, M. bovis BCG and M. smegmatis. Microbiology 148, 3007–17 (2002).
Chuang, Y. M., Belchis, D. A. & Karakousis, P. C. The polyphosphate kinase gene ppk2 is required for Mycobacterium tuberculosis inorganic polyphosphate regulation and virulence. MBio 4, e00039–13 (2013).
Manganelli, R. Sigma Factors: Key Molecules in Mycobacterium tuberculosis Physiology and Virulence. Microbiol Spectr 2, MGM2-0007–2013 (2014).
Parish, T. Two-Component Regulatory Systems of Mycobacteria. Microbiol Spectr 2, MGM2-0010–2013 (2014).
Turner, O. C., Basaraba, R. J. & Orme, I. M. Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with Mycobacterium tuberculosis. Infect Immun 71, 864–71 (2003).
Converse, P. J. et al. Role of the dosR-dosS two-component regulatory system in Mycobacterium tuberculosis virulence in three animal models. Infect Immun 77, 1230–7 (2009).
Jain, S. K. et al. Accelerated detection of Mycobacterium tuberculosis genes essential for bacterial survival in guinea pigs, compared with mice. J Infect Dis 195, 1634–42 (2007).
Green, K. D. & Garneau-Tsodikova, S. Resistance in tuberculosis: what do we know and where can we go? Front Microbiol 4, 208 (2013).
Koul, A., Arnoult, E., Lounis, N., Guillemont, J. & Andries, K. The challenge of new drug discovery for tuberculosis. Nature 469, 483–90 (2011).
Diacon, A. H., Lounis, N. & Dannemann, B. Multidrug-resistant tuberculosis and bedaquiline. N Engl J Med 371, 2436 (2014).
Diacon, A. H. et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360, 2397–405 (2009).
Sievers, F. et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 7, 539 (2011).
Lee, M. H. & Hatfull, G. F. Mycobacteriophage L5 integrase-mediated site-specific integration in vitro. J Bacteriol 175, 6836–41 (1993).
Lasco, T. M., Cassone, L., Kamohara, H., Yoshimura, T. & McMurray, D. N. Evaluating the role of tumor necrosis factor-alpha in experimental pulmonary tuberculosis in the guinea pig. Tuberculosis (Edinb) 85, 245–58 (2005).
Arora, G. et al. High throughput screen identifies small molecule inhibitors specific for Mycobacterium tuberculosis phosphoserine phosphatase. J Biol Chem 289, 25149–65 (2014).
Acknowledgements
The authors thank Department of Biotechnology for extramural funding (BT/HRD/35/02/18/2009 and BT/PR5600/MED/29/543/2012). RS is thankful to DBT for Ramalingaswami research fellowship. The assistance provided by staff members at Tuberculosis Aerosol Challenge Facility (ICGEB) for animal experiments is acknowledged. We also thank Prof. Anil K Tyagi for providing access to BSL-3 for routine microbiology experiments. PT and SA are thankful to DBT for their research fellowship. ICMR is also acknowledged for providing senior research fellowship to GA. We acknowledge Dr. Rohan Dhiman and Ms. Deepika Chaudhary for critical reading of the manuscript. We are grateful to Dr. Ashok Mukherjee for assistance with histopathology analysis. Lab attendant Mr. Rajesh Kumar and Mr. Surender Kumar are acknowledged for their assistance.
Author information
Authors and Affiliations
Contributions
R.S. conceived and supervised the study. M.S., P.T. and S.K. performed biochemical characterization and high throughput screening. M.S., P.T., G.A. and S.A. performed BSL-3 experiments. M.S. and G.A. performed animal experiments. S.A. performed cellular cytotoxicity experiments. R.S. has written the manuscript.
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Electronic supplementary material
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Singh, M., Tiwari, P., Arora, G. et al. Establishing Virulence Associated Polyphosphate Kinase 2 as a drug target for Mycobacterium tuberculosis. Sci Rep 6, 26900 (2016). https://doi.org/10.1038/srep26900
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/srep26900
This article is cited by
-
A high-throughput dual system to screen polyphosphate kinase mutants for efficient ATP regeneration in L-theanine biocatalysis
Biotechnology for Biofuels and Bioproducts (2023)
-
Designing novel possible kinase inhibitor derivatives as therapeutics against Mycobacterium tuberculosis: An in silico study
Scientific Reports (2019)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.